SCHEMBL4128499

SCHEMBL4128499

O=C1N=C(Nc2ccc(C(Br)C(=O)O)c(F)c2)SC1=Cc1cc2ccccc2cc1OCc1ccc(-c2ccccc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PTP4A3 O75365 6/20 0.47
PTPN1 P18031 5/20 0.37
CISD1 Q9NZ45 1/20 0.37
TDP1 Q9NUW8 1/20 0.36
MEN1 O00255 4/20 0.34
KMT2A Q03164 4/20 0.34
POLB P06746 2/20 0.34
NSD2 O96028 1/20 0.33
ALDH1A1 P00352 1/20 0.33
MAPT P10636 1/20 0.33
CRHBP P24387 1/20 0.33
CRHR2 Q13324 1/20 0.33
GPR34 Q9UPC5 1/20 0.33
ALOX5 P09917 1/20 0.33
MAPK1 P28482 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4128497 1.00 PTP4A3 (0.47) PTP4A3PTPN1CISD1TDP1MEN1
SCHEMBL4129153 0.90 PTP4A3 (0.46) PTP4A3PTPN1CISD1TDP1MEN1
SCHEMBL4129152 0.90 PTP4A3 (0.46) PTP4A3PTPN1CISD1TDP1MEN1
SCHEMBL4132551 0.82 PTP4A3 (0.37) PTP4A3CISD1TDP1MEN1KMT2A
SCHEMBL4132553 0.82 PTP4A3 (0.37) PTP4A3CISD1TDP1MEN1KMT2A
SCHEMBL4127484 0.81 MEN1 (0.39) CISD1TDP1MEN1KMT2APOLB
SCHEMBL4127491 0.81 MEN1 (0.39) CISD1TDP1MEN1KMT2APOLB
SCHEMBL4134460 0.80 PTP4A3 (0.36) PTP4A3CISD1TDP1MEN1KMT2A
SCHEMBL4134464 0.80 PTP4A3 (0.36) PTP4A3CISD1TDP1MEN1KMT2A
SCHEMBL4133819 0.79 PTP4A3 (0.45) PTP4A3PTPN1CISD1TDP1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US claimed
EP-1934192-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS Torrent Pharmaceuticals Ltd (IN) 2008-06-25 EP claimed
WO-2007032028-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS TORRENT PHARMACEUTICALS LTD. (IN) 2007-03-22 WO claimed
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US disclosed
EP-1934192-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS Torrent Pharmaceuticals Ltd (IN) 2008-06-25 EP disclosed
WO-2007032028-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS TORRENT PHARMACEUTICALS LTD. (IN) 2007-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors PTPRF, PTPA, PTPRJ PTP4A3 26/4885PTPN1 7/4885CISD1 3041/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.